Ipragliflozin, a sodium-glucose cotransporter 2 inhibitor, ameliorates the development of liver fibrosis in diabetic Otsuka Long-Evans Tokushima fatty rats.
about
Rationale and design of a multicenter randomized controlled study to evaluate the preventive effect of ipragliflozin on carotid atherosclerosis: the PROTECT study.The effect of SGLT2 inhibitors on cardiovascular events and renal function.Effects of canagliflozin, an SGLT2 inhibitor, on hepatic function in Japanese patients with type 2 diabetes mellitus: pooled and subgroup analyses of clinical trials.Metabolic effects of Tofogliflozin are efficiently enhanced with appropriate dietary carbohydrate ratio and are distinct from carbohydrate restriction.
P2860
Ipragliflozin, a sodium-glucose cotransporter 2 inhibitor, ameliorates the development of liver fibrosis in diabetic Otsuka Long-Evans Tokushima fatty rats.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Ipragliflozin, a sodium-glucos ...... ng-Evans Tokushima fatty rats.
@en
Ipragliflozin, a sodium-glucos ...... ng-Evans Tokushima fatty rats.
@nl
type
label
Ipragliflozin, a sodium-glucos ...... ng-Evans Tokushima fatty rats.
@en
Ipragliflozin, a sodium-glucos ...... ng-Evans Tokushima fatty rats.
@nl
prefLabel
Ipragliflozin, a sodium-glucos ...... ng-Evans Tokushima fatty rats.
@en
Ipragliflozin, a sodium-glucos ...... ng-Evans Tokushima fatty rats.
@nl
P2093
P2860
P1476
Ipragliflozin, a sodium-glucos ...... ong-Evans Tokushima fatty rats
@en
P2093
Akitoshi Douhara
Hideto Kawaratani
Hitoshi Yoshiji
Kei Moriya
Kiyoshi Asada
Kosuke Takeda
Mitsuteru Kitade
Norihisa Nishimura
Tadashi Namisaki
Yasushi Okura
P2860
P304
P356
10.1007/S00535-016-1200-6
P577
2016-03-29T00:00:00Z